Cargando…

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults

OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompr...

Descripción completa

Detalles Bibliográficos
Autores principales: Atwood, Mark, Beausoleil, Linda, Breton, Marie-Claude, Laferriere, Craig, Sato, Reiko, Weycker, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267650/
https://www.ncbi.nlm.nih.gov/pubmed/29981104
http://dx.doi.org/10.17269/s41997-018-0050-9
_version_ 1783376123666628608
author Atwood, Mark
Beausoleil, Linda
Breton, Marie-Claude
Laferriere, Craig
Sato, Reiko
Weycker, Derek
author_facet Atwood, Mark
Beausoleil, Linda
Breton, Marie-Claude
Laferriere, Craig
Sato, Reiko
Weycker, Derek
author_sort Atwood, Mark
collection PubMed
description OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompromised. In light of recent PCV13 efficacy data from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), and new sero-epidemiology data on community-acquired pneumonia (CAP), we examined the economic implications of funding an expanded adult pneumococcal immunization program in Canada. METHODS: A microsimulation model depicting expected lifetime risks, consequences, and costs of invasive pneumococcal disease (IPD) and CAP was developed. PPV23 effectiveness was based on published literature, and PCV13 effectiveness was based on CAPiTA; all other model parameters were based on published data or secondary sources. Herd effects from the PCV13 pediatric program were considered. Outcomes and costs were evaluated assuming use of PPV23 alone, and alternatively, use of PCV13 → PPV23 among (1) all adults aged ≥ 65 years (n = 5.4 M) and (2) immunocompromised and high-risk adults aged ≥ 65 years (n = 3.0 M). RESULTS: For population no. 1, PCV13 → PPV23 reduced IPD cases by 1100, CAP cases by 7000, and disease costs by $135.8M; vaccination costs increased by $254.3M, and cost per QALY gained was $35,484. For population no. 2, PCV13 → PPV23 reduced IPD cases by 900, CAP cases by 6000, and disease costs by $120.3M; vaccination costs increased by $149.8M, and cost per QALY gained was $10,728. CONCLUSION: Expanding use of PCV13 → PPV23 by funding PCV13 among Canadian adults aged ≥ 65 would be a cost-effective use of healthcare resources. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-018-0050-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6267650
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-62676502018-12-18 Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults Atwood, Mark Beausoleil, Linda Breton, Marie-Claude Laferriere, Craig Sato, Reiko Weycker, Derek Can J Public Health Quantitative Research OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompromised. In light of recent PCV13 efficacy data from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), and new sero-epidemiology data on community-acquired pneumonia (CAP), we examined the economic implications of funding an expanded adult pneumococcal immunization program in Canada. METHODS: A microsimulation model depicting expected lifetime risks, consequences, and costs of invasive pneumococcal disease (IPD) and CAP was developed. PPV23 effectiveness was based on published literature, and PCV13 effectiveness was based on CAPiTA; all other model parameters were based on published data or secondary sources. Herd effects from the PCV13 pediatric program were considered. Outcomes and costs were evaluated assuming use of PPV23 alone, and alternatively, use of PCV13 → PPV23 among (1) all adults aged ≥ 65 years (n = 5.4 M) and (2) immunocompromised and high-risk adults aged ≥ 65 years (n = 3.0 M). RESULTS: For population no. 1, PCV13 → PPV23 reduced IPD cases by 1100, CAP cases by 7000, and disease costs by $135.8M; vaccination costs increased by $254.3M, and cost per QALY gained was $35,484. For population no. 2, PCV13 → PPV23 reduced IPD cases by 900, CAP cases by 6000, and disease costs by $120.3M; vaccination costs increased by $149.8M, and cost per QALY gained was $10,728. CONCLUSION: Expanding use of PCV13 → PPV23 by funding PCV13 among Canadian adults aged ≥ 65 would be a cost-effective use of healthcare resources. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-018-0050-9) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-05-09 /pmc/articles/PMC6267650/ /pubmed/29981104 http://dx.doi.org/10.17269/s41997-018-0050-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Quantitative Research
Atwood, Mark
Beausoleil, Linda
Breton, Marie-Claude
Laferriere, Craig
Sato, Reiko
Weycker, Derek
Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
title Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
title_full Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
title_fullStr Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
title_full_unstemmed Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
title_short Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
title_sort cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (pcv13) in canadian adults
topic Quantitative Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267650/
https://www.ncbi.nlm.nih.gov/pubmed/29981104
http://dx.doi.org/10.17269/s41997-018-0050-9
work_keys_str_mv AT atwoodmark costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults
AT beausoleillinda costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults
AT bretonmarieclaude costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults
AT laferrierecraig costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults
AT satoreiko costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults
AT weyckerderek costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults